Track topics on Twitter Track topics that are important to you
Ebixa is an effective, safe and well tolerated therapy, that helps overcome the everyday challenges in Alzheimer’s disease, easing the lives of both patients and their carers. Ebixa is indicated for the treatment of moderate to severe Alzheimer’s disease. Ebixa is a specific, uncompetitive NMDA-receptor antagonist, with a novel mechanism of action that targets the glutamatergic signalling in the brain.
H. Lundbeck A/S Ottiliavej 9
Phone: 45 36 30 13 11
Fax: 45 36 30 19 40
The aim of the present study was to examine the influence of memantine, a noncompetitive NMDA receptor blocker, in depression co-morbid with long term alcohol heavy use comparing to SSRI-i...
The purpose of this trial is to study the effect of Memantine (uncompetitive, moderate affinity, NMDA receptor antagonist that binds to the NMDA receptor channel, and regulates the calciu...
Ebixa is an effective, safe and well tolerated therapy, that helps overcome the everyday challenges in Alzheimer’s disease, easing the lives of both patients and their carers. Ebixa is indicated for...
We have published hundreds of Ebixa news stories on BioPortfolio along with dozens of Ebixa Clinical Trials and PubMed Articles about Ebixa for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Ebixa Companies in our database. You can also find out about relevant Ebixa Drugs and Medications on this site too.
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase 'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...